Search
Search Results
-
Chinese Preclinical Alzheimer’s Disease Study (C-PAS): Design and Challenge from PET Acceptance
BackgroundLarge-scale preclinical Alzheimer’s disease study based on β-amyloid positron emission tomography (PET) has not been conducted in China.
...
-
The AlzMatch Pilot Study - Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer’s Disease Trials
BackgroundAdvances in plasma biomarkers to detect Alzheimer’s disease (AD) biology allows researchers to improve the efficiency of participant...
-
Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer’s disease? From preclinical studies to the clinical trials
Protein kinases (PKs) have emerged as one of the most intensively investigated drug targets in current pharmacological research, with indications...
-
Development of a smartphone screening test for preclinical Alzheimer’s disease and validation across the dementia continuum
BackgroundDementia prevalence is predicted to triple to 152 million globally by 2050. Alzheimer’s disease (AD) constitutes 70% of cases. There is an...
-
Usability of a Web-Based Registry for Preclinical Alzheimer’s Disease: Implications from a Cross-Sectional Online Survey
BackgroundWe have been conducting a Japanese trial-ready cohort web study since 2019 as a web-based online registry to enroll individuals with...
-
Progress on early diagnosing Alzheimer’s disease
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects both cognition and non-cognition functions. The disease follows a...
-
Sensitivity of the Preclinical Alzheimer’s Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer’s Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial
BackgroundCognitive composites commonly serve as primary outcomes in Alzheimer’s disease (AD) secondary prevention trials.
ObjectiveTo evaluate the...
-
Cohort-Specific Optimization of Models Predicting Preclinical Alzheimer’s Disease, to Enhance Screening Performance in the Middle of Preclinical Alzheimer’s Disease Clinical Studies
BackgroundModels that can predict brain amyloid beta (Aβ) status more accurately have been desired to identify participants for clinical trials of...
-
Associations of tau, Aβ, and brain volume of the Papez circuit with cognition in Alzheimer’s disease
This study aimed to investigate the cross-sectional associations between regional Alzheimer’s disease (AD) biomarkers, including tau, β-amyloid (Aβ),...
-
Continuous Associations between Remote Self-Administered Cognitive Measures and Imaging Biomarkers of Alzheimer’s Disease
BackgroundEasily accessible and self-administered cognitive assessments that can aid early detection for Alzheimer’s disease (AD) dementia risk are...
-
Clinical Correlates of the PET-based Braak Staging Framework in Alzheimer’s Disease
In vivo Alzheimer’s disease diagnosis and staging is traditionally based on clinical features. However, the agreement between clinical and...
-
Targeting Endogenous Mechanisms of Brain Resilience for the Treatment and Prevention of Alzheimer’s Disease
Alzheimer’s disease is a neurodegenerative disorder which contributes to millions of cases of dementia worldwide. The dominant theoretical models of...
-
The Room Where It Happens: Clinician Reflections on Returning Preclinical Alzheimer’s Biomarker Results to Research Participants
Disclosing Alzheimer’s disease (AD) biomarkers to research participants is a growing practice. Here, we aim to synthesize the experiences of...
-
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification
Novel agents addressing non-amyloid, non-tau targets in Alzheimer’s Disease (AD) comprise 70% of the AD drug development pipeline of agents currently...
-
Anti-amyloid Antibody Therapies for Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common cause of dementia, which is characterized by a progressive neurodegenerative disorder that is extremely...
-
Mendelian Randomization Analysis Reveals Causal Factors behind Alzheimer’s Disease Risk: Evidence, Opportunities, and Challenges
Alzheimer’s disease and its comorbidities pose a heavy disease burden globally, and its treatment remains a major challenge. Identifying the...
-
Clinical importance in Alzheimer’s disease: effects of anchor agreement and disease severity
ObjectivesMethods of evaluating clinically meaningful decline are critical in research on Alzheimer’s disease. A common method of quantifying...
-
Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer’s Disease. Are We Ready for the New Era?
Recent positive trials for novel disease modifying therapies of anti-amyloid monoclonal antibodies represent a paradigm shift in the prevention and...
-
Soluble TREM2 in body fluid in Alzheimer’s disease and Parkinson’s disease
BackgroundPrevious studies showed conflicting results regarding soluble triggering receptor expressed on myeloid cells 2 (sTREM2) level alteration in...
-
Evaluating the effect of rapamycin treatment in Alzheimer’s disease and aging using in vivo imaging: the ERAP phase IIa clinical study protocol
BackgroundRapamycin is an inhibitor of the mechanistic target of rapamycin (mTOR) protein kinase, and preclinical data demonstrate that it is a...
